Novartis
Search results
1 day ago · Sandoz has announced the European launch of Pyzchiva, a ustekinumab biosimilar approved for the treatment of several autoimmune conditions including psoriasis and Crohn’s disease. Pyzchiva is a ...
21 hours ago · In a press release, Sandoz points out that Europe has the highest prevalence of psoriasis in the world, with 6.4 million people affected. Last September, Sandoz signed an agreement with Samsung Bioepis giving it the right to market a generic version of ustekinumab in the United States, Canada, Europe, the United Kingdom and Switzerland.
1 day ago · Sandoz has announced the launch of Pyzchiva®* (ustekinumab) across Europe. Pyzchiva®, developed and registered by Samsung Bioepis, is the first ustekinumab biosimilar to launch in Europe with all reference medicine strengths, including the 130mg vial initiation dose for Crohn’s disease.
1 day ago · Swiss generics and biosimilars major Sandoz (SIX: SDZ) announced the launch of Pyzchiva (ustekinumab) across Europe, starting today. The original drug is marketed by US healthcare giant Johnson & Johnson (NYSE: JNJ) under the trade name Stelara, which generated global sales of Annual: $10.86 billion last year.
2 days ago · China accounted for about 10% of Aspen's global revenue, Merizalde said before the Sandoz deal was announced, but it is only one of the dozens of countries where Africa's biggest pharmaceutical ...
1 day ago · Sandoz, CIBA-Geigy, Roche and the Basel hub of the pharmaceutical industry all have their roots in this boom. 1900s - Aspirin arrives It wasn’t just Swiss companies that had their roots in the ...
1 day ago · Latest Sandoz Group AG (SDZ:SWX) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.
